“Comparative Efficacy of Anastrozole, Letrozole, and Fulvestrant as Endocrine Partners Combined with CDK4/6 Inhibitors in Patients with HR+/HER2– Metastatic Breast Cancer: A Real-World Evidence from the Stavropol Regional Clinical Oncology Center” (2025) Voprosy onkologii, 71(6), p. OF-2376. doi:10.37469/0507-3758-2025-71-6-OF-2376.